MENLO PARK, Calif.--(BUSINESS WIRE)--SRI International, an independent nonprofit research and development organization, today announced that it has been awarded a $9.5 million contract by the Defense Threat Reduction Agency (DTRA), part of the U.S. Department of Defense. SRI will lead a drug discovery and development program to identify approved drugs that could also be effective against biological threats. The goal of the program is to repurpose drugs that are currently approved and marketed but have not been previously evaluated against diseases caused by biological weapons.
